Compare WGO & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | ARVN |
|---|---|---|
| Founded | 1958 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.5M | 600.2M |
| IPO Year | 1994 | 2018 |
| Metric | WGO | ARVN |
|---|---|---|
| Price | $23.48 | $7.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 16 |
| Target Price | ★ $37.80 | $13.93 |
| AVG Volume (30 Days) | 597.2K | ★ 797.9K |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.84% | N/A |
| EPS Growth | ★ 106.82 | 58.84 |
| EPS | 0.87 | ★ 1.70 |
| Revenue | ★ $1,985,674,000.00 | $262,600,000.00 |
| Revenue This Year | N/A | $12.76 |
| Revenue Next Year | $4.36 | N/A |
| P/E Ratio | $28.33 | ★ $4.42 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.13 | $6.97 |
| 52 Week High | $50.16 | $14.22 |
| Indicator | WGO | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 23.92 | 42.54 |
| Support Level | N/A | N/A |
| Resistance Level | $30.90 | $8.52 |
| Average True Range (ATR) | 0.84 | 0.32 |
| MACD | -0.20 | 0.01 |
| Stochastic Oscillator | 0.00 | 33.10 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2010 with the acquisition of SunnyBrook and acquired Grand Design in 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in 2019, and acquired Barletta pontoon boats in 2021. It also is developing electric and autonomous technology.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.